Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Delta-containing extrasynaptic gamma-aminobutyric acid type A receptors (δ-GABAARs) are a specialized subclass of ionotropic GABA receptors located outside the synaptic cleft, primarily in brain regions such as the hippocampus, thalamus, and cerebellum (Brickley & Mody, 2012). Unlike synaptic receptors that mediate rapid, phasic inhibition, δ-containing receptors respond to low concentrations of ambient GABA to provide a persistent, 'tonic' inhibitory current that regulates the overall excitability and 'tone' of neurons (Belelli & Lambert, 2005). These receptors are typically composed of α4βδ or α6βδ subunits and are uniquely sensitive to endogenous neurosteroids, which act as potent positive allosteric modulators (Maguire & Mody, 2008). Dysregulation of δ-GABAAR expression is strongly linked to the pathophysiology of postpartum depression and epilepsy, where fluctuations in neurosteroid levels fail to be compensated by receptor plasticity (Walton & Maguire, 2019). Therapeutic targeting of these receptors with synthetic neurosteroids like brexanolone and zuranolone has proven effective in rapidly alleviating depressive symptoms by enhancing tonic inhibitory signaling (Gunduz-Bruce et al., 2019).
Positive allosteric modulation of the GABA-A receptor chloride channel, increasing the frequency and/or duration of channel opening in response to GABA, and direct agonism at higher concentrations (Belelli & Lambert, 2005; Maguire & Mody, 2008).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Delta-containing extrasynaptic gamma-aminobutyric acid type A receptor (δ-GABAAR).